<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02092974</url>
  </required_header>
  <id_info>
    <org_study_id>LESO</org_study_id>
    <nct_id>NCT02092974</nct_id>
  </id_info>
  <brief_title>Mechanism of tDCS-induced Learning Enhancement - the Role of Serotonin</brief_title>
  <acronym>LESO</acronym>
  <official_title>Mechanism of tDCS-induced Learning Enhancement - the Role of Serotonin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess whether the application of a selective serotonin reuptake
      inhibitor (SSRI) enhances and prolongs the learning enhancement achieved by anodal
      transcranial direct current stimulation (atDCS). For this, young and older healthy subjects
      will be tested with a well established learning paradigm. Results of this study may help to
      support the application of atDCS also in patients, e.g. with dementia or mild cognitive
      impairment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recall score after learning under tDC stimulation + SSRI compared to learning under tDC stimulation + placebo.</measure>
    <time_frame>immediately after end of learning phase (approx. 1 hour)</time_frame>
    <description>Recall score immediately after learning phase (=training of visual-spatial abilities) under tDC stimulation + SSRI application compared to learning under tDC stimulation + placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>prolongation of the atDCS induced learning enhancement by SSRI</measure>
    <time_frame>1 week</time_frame>
    <description>Measurement of recall scores on the evening of the same day after the learning phase (+tDCS + SSRI), the morning of the day after and 1 week later in order to assess the prolongation of atDCS induced learning enhancement by the SSRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase of learning enhancement by atDCS + placebo or sham-tDCS + SSRI vs. sham-tDCS + placebo</measure>
    <time_frame>immediately after learning phase (approx. 1 hour)</time_frame>
    <description>Measurement of recall scores directly after learning phase after application of atDCS + placebo or sham-tDCS + SSRI vs. sham-tDCS + placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>prolongation of learning enhancement by atDCS + placebo or sham-tDCS + SSRI vs. sham-tDCS + placebo</measure>
    <time_frame>1 week</time_frame>
    <description>Measurement of recall scores on the evening of the same day of learning phase, the morning of the day after and 1 week later under application of atDCS + placebo or sham-tDCS + SSRI vs. sham-tDCS + placebo, in order to assess prolongation of learning enhancement by SSRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>genotyping of learning related polymorphisms</measure>
    <time_frame>once</time_frame>
    <description>To assess predictors of SSRI-enhanced brain stimulation, genotyping of several learning related polymorphisms will be performed (i.e., APOE, BDNF, Val66Met, COMT, Val158Met, KIBRA, rs17070145, 5-Hydroxytryptamine transporter).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Young and Older Adults</condition>
  <arm_group>
    <arm_group_label>tDCS + SSRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>tDCS + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>sham-tDCS + SSRI</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>sham-DCS + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>tDCS</intervention_name>
    <arm_group_label>tDCS + SSRI</arm_group_label>
    <arm_group_label>tDCS + placebo</arm_group_label>
    <other_name>transcranial direct current stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram</intervention_name>
    <arm_group_label>tDCS + SSRI</arm_group_label>
    <arm_group_label>sham-tDCS + SSRI</arm_group_label>
    <other_name>SSRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sham-tDCS + placebo</intervention_name>
    <arm_group_label>sham-DCS + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  right handedness

          -  unobtrusive neuropsychological screening

          -  ability to provide written informed consent

          -  no pathological findings in head MRI

          -  age: 18 to 35 years (young adults) or 50-80 years (older adults)

          -  Highly effective contraception (Pearl Index &lt; 1) or reliable abstinence from any
             heterosexual relationships in women of childbearing potential

        Exclusion Criteria:

          -  severe internal or psychiatric disease (especially depression or suicidal thoughts)

          -  epilepsy

          -  cognitive impairment (&lt; SD under age adjusted norm in neuropsychological testing)

          -  concurrent taking of serotonin precursors (tryptophan, 5-HTP) or MAO inhibitors

          -  concurrent taking of tramadol or triptans

          -  concurrent taking of pimozide or linezolid

          -  concurrent taking of other drugs prolonging the QT-interval

          -  long-QT-syndrome

          -  hypokalemia or hypomagnesemia

          -  known intolerance of the study medication

          -  claustrophobia or metallic implants, tattoos (MRI exclusion criteria)

          -  pregnancy or lactation

          -  participation in another drug-interventional clinical trial within the last month or
             during the entire study

          -  probands that are placed in an institution due to official or judicial order

          -  non-agreement to save and transmit pseudonymised study data within the clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agnes Flöel, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charite Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Prehn K, Stengl H, Grittner U, Kosiolek R, Ölschläger A, Weidemann A, Flöel A. Effects of Anodal Transcranial Direct Current Stimulation and Serotonergic Enhancement on Memory Performance in Young and Older Adults. Neuropsychopharmacology. 2017 Jan;42(2):551-561. doi: 10.1038/npp.2016.170. Epub 2016 Aug 24.</citation>
    <PMID>27555381</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2014</study_first_submitted>
  <study_first_submitted_qc>March 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2014</study_first_posted>
  <last_update_submitted>July 4, 2017</last_update_submitted>
  <last_update_submitted_qc>July 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Agnes Flöel</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>transcranial direct current stimulation (tDCS)</keyword>
  <keyword>selective serotonin reuptake inhibitor (SSRI)</keyword>
  <keyword>young</keyword>
  <keyword>older adults</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Serotonin</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

